What is the current price and short-term outlook for MBOT stock?

MBOT stock trades at **$2.12 USD** pre market on 18 Feb 2026. Short-term outlook is mixed with RSI **57.25** and ADX **27.15**; catalysts include earnings on 25 Feb 2026 and clinical updates that could move the price materially.

What valuation metrics matter for MBOT stock?

Key metrics: PE is negative (**-4.71**), price-to-book about **1.34**, cash per share **$1.67**, and current ratio **27.53**. These show liquidity but also indicate pre-revenue status and reliance on R&D progress.

How does Meyka AI view MBOT stock?

Meyka AI rates MBOT with a score out of 100: **70.51** (Grade **B+**, Suggestion: **BUY**). The grade considers benchmarks, sector performance, growth, key metrics and analyst consensus.

What is Meyka AI's price forecast for MBOT stock?

Meyka AI's forecast model projects a yearly price of **$4.06 USD**, which implies **91.26%** upside from **$2.12**. Forecasts are model-based projections and not guarantees.

US Stocks

$2.12 Pre Market 18 Feb 2026: MBOT Microbot Medical Inc NASDAQ – 91% upside

ByDanny Kontos February 18, 2026

MBOT stock trades at $2.12 pre market on 18 Feb 2026, down 2.30% from the prior close. Microbot Medical Inc. (MBOT) on the NASDAQ shows a market cap of $96,609,316.00 and rising short-term momentum as investors await a key earnings update on 25 Feb 2026. We examine valuation, technicals, and model forecasts to frame an AI-driven view of risk and potential upside for MBOT stock.